RxDoctor Payments Data

Sasikanth Adigopula, MD

Advanced Heart Failure and Transplant Cardiology · Indianapolis, INNPI 1053325050

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $268,400 of the $310,239 with a category attached, or 86.5%. 24 manufacturers reported payments, led by Boehringer Ingelheim at 42.0% of the total. 2025 is the largest year on record at $118,352, more than ten times the $372 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$310,239in general payments, 2019–2025

Across 308 payments — averaging $1007.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$130K
  • Actelion Pharmaceuticals US, Inc.$54K
  • AstraZeneca$42K
  • United Therapeutics Corporation$41K
  • Lilly USA, LLC$21K
  • Abbott$11K
  • plus $9K from 18 others
$892,333in research payments, 2019–2025

Across 186 payments — averaging $4797.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • United Therapeutics Corporation$450K
  • Boston Scientific$383K
  • Abbott$37K
  • CSL Behring$22K

What the payments were for

  • Consulting fees$12,0384%
  • Speaking & faculty fees$268,40087%
  • Travel & lodging$21,3877%
  • Food & beverage$8,2303%
  • Education$1840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,239 in reported general payments places this provider in the 95th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.

See all advanced heart failure and transplant cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$37,362
Medicare patients
162
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag12$279,740
VyndamaxTafamidis11$237,705
OpsumitMacitentan13$160,512
CamzyosMavacamten20$159,017
JardianceEmpagliflozin114$96,073
EntrestoSacubitril/Valsartan78$79,804
FarxigaDapagliflozin Propanediol41$44,521
Orenitram ErTreprostinil Diolamine12$42,543
EliquisApixaban17$16,789
CorlanorIvabradine Hcl15$12,310
Tadalafil19$1,502
Torsemide53$934
Metoprolol Succinate37$553
Potassium Chloride12$287
Spironolactone45$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$54,165$440,25225 claims
PfizerVyndamax, Eliquis$47$254,49428 claims
E.r. Squibb & Sons, L.L.C.Camzyos$130$159,01720 claims
Boehringer IngelheimJardiance$130,352$96,073114 claims
NovartisEntresto$71$79,80478 claims
AstraZenecaFarxiga$42,414$44,52141 claims
AmgenCorlanor$71$12,31015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 advanced heart failure and transplant cardiology providers in Indiana.

Other advanced heart failure and transplant cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →